C07D 241/50
With hetero atoms directly attached to ring nitrogen atoms
Official title: with hetero atoms directly attached to ring nitrogen atoms
C07D241/50 (With hetero atoms directly attached to ring nitrogen atoms) appears on 208 US grants and 132 published applications in this corpus.
Search patents in C07D- Granted patents
- 208
- Published applications
- 132
- Assignees
- 136
- Inventors
- 527
- Latest grant
- 29 Apr 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 17 | 0 |
| 1977 | 7 | 0 |
| 1978 | 4 | 0 |
| 1979 | 1 | 0 |
| 1980 | 5 | 0 |
| 1981 | 5 | 0 |
| 1982 | 7 | 0 |
| 1983 | 6 | 0 |
| 1984 | 0 | 0 |
| 1985 | 3 | 0 |
| 1986 | 2 | 0 |
| 1987 | 7 | 0 |
| 1988 | 2 | 0 |
| 1989 | 4 | 0 |
| 1990 | 2 | 0 |
| 1991 | 4 | 0 |
| 1992 | 4 | 0 |
| 1993 | 1 | 0 |
| 1994 | 5 | 0 |
| 1995 | 4 | 0 |
| 1996 | 3 | 0 |
| 1997 | 9 | 0 |
| 1998 | 12 | 0 |
| 1999 | 1 | 0 |
| 2000 | 2 | 0 |
| 2001 | 3 | 2 |
| 2002 | 3 | 3 |
| 2003 | 6 | 5 |
| 2004 | 4 | 4 |
| 2005 | 3 | 6 |
| 2006 | 0 | 4 |
| 2007 | 2 | 3 |
| 2008 | 1 | 5 |
| 2009 | 3 | 6 |
| 2010 | 3 | 6 |
| 2011 | 3 | 4 |
| 2012 | 2 | 7 |
| 2013 | 5 | 7 |
| 2014 | 8 | 9 |
| 2015 | 8 | 14 |
| 2016 | 5 | 4 |
| 2017 | 4 | 5 |
| 2018 | 4 | 7 |
| 2019 | 3 | 6 |
| 2020 | 6 | 5 |
| 2021 | 6 | 8 |
| 2022 | 6 | 2 |
| 2023 | 1 | 4 |
| 2024 | 1 | 3 |
| 2025 | 1 | 2 |
| 2026 | 0 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Small molecules that sensitize HIV-1 infected cells to antibody dependent cellular cytotoxicity29 Apr 2025US 12,286,401 B2The Trustees of the University of Pennsylvania
- Substituted phenazines and methods of treating cancer and bacterial diseases16 Apr 2024US 11,958,842 B2Adjutec Pharma AS
- Methods for 1,4-diazo N-heterocycle synthesis29 Aug 2023US 11,739,062 B2Purdue Research Foundation
- Piperazine-2,5-diones as TGF-beta inhibitors22 Nov 2022US 11,505,531 B2Southern Research Institute
- ACLY inhibitors and uses thereof8 Nov 2022US 11,492,341 B2Nimbus Artemis, Inc.
- Inhibitors of spns2 and uses thereof16 Jul 2026US 2026/0200896 A1New York University
- Small molecules that sensitize hiv-1 infected cells to antibody dependent cellular cytotoxicity24 Jul 2025US 2025/0236593 A1The Trustees of the University of Pennsylvania
- 3,4-dihydroquinoxaline-2-carboximide derivative compound and pharmaceutical composition comprising same for preventing or treating cancer disease3 Jul 2025US 2025/0214947 A1Cureverse Incorporated
- Benzopiperazine and related analogs for inhibiting yap/taz-tead12 Dec 2024US 2024/0409556 A1Katholieke Universiteit Leuven
- Bisdiaminophenyl compound, crosslinking agent, composition, and molded article14 Mar 2024US 2024/0084102 A1Daikin Industries, Ltd.
Most cited
By later US patents
- Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases232US 6,180,632 B2Aventis Pharmaceuticals Products Inc. · 2001
- Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase226US 5,480,883 ARhone-Poulenc Rorer Pharmaceuticals Inc. · 1996
- Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases219US 6,482,834 B2Aventis Pharmaceuticals Inc. · 2002
- Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase209US 5,409,930 ARhone-Poulenc Rorer Pharmaceuticals Inc. · 1995
- Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases207US 6,245,760 B1Aventis Pharmaceuticals Products Inc. · 2001